Ellicott City, M.D., May 11, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year collaboration with Myoderm, a global leader and specialist in sourcing, distribution, and management of comparator drugs and other pharmaceutical products and supplies for clinical research. Myoderm will participate as a Global Impact Partner (GIP) and align with sponsors, CROs and other industry solution providers who share an ongoing commitment to promoting site sustainability across the clinical trials landscape.
“SCRS is pleased to welcome Myoderm as our newest Global Impact Partner,” comments Christine Pierre, SCRS President. “Collaboration with Myoderm will incite dialogue around drug and product sourcing for clinical trials; factors which can affect individual sites. Myoderm has supply chain experience that factors into trial design, and can be shared to gain efficiencies in the processes currently being used.”
“We are honored to be a part of and collaborate with such an innovative organization and group of professionals,” Michael Cohen, Managing Director of Myoderm, remarks. “For more than 25 years we have focused on developing clinical trial supply solutions for sponsors, CROs and research sites alike. We see this partnership as an opportunity to make further advancements to the supply chain, alleviating pressure on research sites and positively impacting patients that benefit from new therapies being developed.”
As a Global Impact Partner (GIP), Myoderm will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.